The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Drug: invega sustenna     Quarter: 2016Q3

Total Drug/Injury Combinations: 380     Number of Pages: 19

DRUGNAME PT EventCount
INVEGA SUSTENNA Laceration 3 view events
INVEGA SUSTENNA Muscle disorder 3 view events
INVEGA SUSTENNA Myalgia 3 view events
INVEGA SUSTENNA Priapism 3 view events
INVEGA SUSTENNA Product leakage 3 view events
INVEGA SUSTENNA Psychiatric decompensation 3 view events
INVEGA SUSTENNA Psychiatric symptom 3 view events
INVEGA SUSTENNA Recurrent cancer 3 view events
INVEGA SUSTENNA Sensory loss 3 view events
INVEGA SUSTENNA Snoring 3 view events
INVEGA SUSTENNA Staring 3 view events
INVEGA SUSTENNA Tobacco user 3 view events
INVEGA SUSTENNA Underdose 3 view events
INVEGA SUSTENNA Weight fluctuation 3 view events
INVEGA SUSTENNA Weight loss poor 3 view events
INVEGA SUSTENNA White blood cell count decreased 3 view events
INVEGA SUSTENNA Abulia 2 view events
INVEGA SUSTENNA Attention deficit/hyperactivity disorder 2 view events
INVEGA SUSTENNA Back disorder 2 view events
INVEGA SUSTENNA Blood pressure fluctuation 2 view events

Total Drug/Injury Combinations: 380     Number of Pages: 19

NOTE: EventCount numbers on this page include duplicate entries from event reports. (e.g. One event has DrugX entered twice, which equals 2 on this page.) The "view events" page treats these duplicates as single entries. (e.g. The 2 entries of DrugX for a single event are counted as 1 instance.)